GANX earnings date and last-quarter result: next report 2026-08-11, last quarter in line, P/E -3.17. Updated 2026-07-23.
Gain Therapeutics (GANX) Research Hub
Gain Therapeutics (GANX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.15 USD (-8.73%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.17, market cap 0.08B. This hub links to the full technical, earnings and options research available for GANX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.15 USD (-8.73%) |
| 52-week range | 1.14 USD – 2.37 USD |
| Trend regime | Range |
| 14-day RSI | 16.7 (Oversold) |
| Trailing P/E | -3.17 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for GANX
Covered Call on GANX: how it works, illustrative setup around the real 1.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GANX: how it works, illustrative setup around the real 1.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GANX: how it works, illustrative setup around the real 1.15 USD price, max profit/loss, breakeven and when to use it. Educational.
GANX technical analysis: range, last 1.15 USD, RSI 16.7, 52w range 1.14 USD–2.37 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GANX in?
Gain Therapeutics (GANX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GANX in an uptrend or downtrend?
As of 2026-10-26, GANX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GANX's trailing P/E ratio?
GANX's trailing P/E is -3.17, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does GANX next report earnings?
GANX is next scheduled to report earnings on 2026-08-11.